The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $133.40

Today's change-1.23 -0.91%
Updated August 18 4:00 PM EDT. Delayed by at least 15 minutes.
 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $133.40

Today's change-1.23 -0.91%
Updated August 18 4:00 PM EDT. Delayed by at least 15 minutes.

Alexion Pharmaceuticals Inc down (U.S.)$1.23

Alexion Pharmaceuticals Inc closed lower Friday, dropping (U.S.)$1.23 or 0.91% to (U.S.)$133.40. Over the last five days, shares have gained 0.35% and 9.03% year to date. Shares have underperformed the S&P 500 by 10.17% during the last year.

Key company metrics

  • Open(U.S.) $134.28
  • Previous close(U.S.) $134.63
  • High(U.S.) $134.92
  • Low(U.S.) $132.99
  • Bid / Ask(U.S.) $110.00 / (U.S.) $136.50
  • YTD % change+9.03%
  • Volume1,416,384
  • Average volume (10-day)1,283,384
  • Average volume (1-month)1,587,533
  • Average volume (3-month)2,688,240
  • 52-week range(U.S.) $96.18 to (U.S.) $145.42
  • Beta1.44
  • Trailing P/E57.81×
  • P/E 1 year forward24.02×
  • Forward PEG1.31×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.31
Updated August 18 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.54%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue912870831799
Total other revenue--------
Total revenue912870831799
Gross profit828801763728
Total cost of revenue84696771
Total operating expense686658704620
Selling / general / administrative265262260230
Research & development199219206196
Depreciation / amortization80808082
Interest expense (income), net operating--------
Unusual expense (income)58289141
Other operating expenses, total--------
Operating income226212127179
Interest income (expense), net non-operating-24-24-25--
Gain (loss) on sale of assets--------
Other--------
Income before tax206194104158
Income after tax1651709294
Income tax, total41241264
Net income1651709294
Total adjustments to net income--------
Net income before extra. items1651709294
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1651709294
Inc. avail. to common incl. extra. items1651709294
Diluted net income1651709294
Dilution adjustment--------
Diluted weighted average shares225226228226
Diluted EPS excluding extraordinary itemsvalue per share0.730.750.400.42
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share0.940.860.760.53